TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial
Press Releases
TransCode Therapeutics, Inc.  
February 6, 2025

TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial

No significant safety or dose limiting toxicities reportedPK data from Cohorts 1 and 2 consistent with preclinical and Phase 0 trial results

logo salamanca press

Salamanca Press

Local & Social